Sinovac Biotech Ltd.
SVA · NASDAQ
6/30/2024 | 12/31/2023 | 6/30/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Revenue | – | $308 | $140 | $280 |
| % Growth | – | 119.3% | -49.9% | – |
| Cost of Goods Sold | – | $0 | $188 | $430 |
| Gross Profit | – | $308 | -$48 | -$150 |
| % Margin | – | 100% | -34.2% | -53.3% |
| R&D Expenses | – | $193 | $151 | $258 |
| G&A Expenses | – | $0 | $0 | $0 |
| SG&A Expenses | – | $177 | $231 | $671 |
| Sales & Mktg Exp. | – | $0 | $0 | $0 |
| Other Operating Expenses | – | $0 | $0 | $0 |
| Operating Expenses | – | $370 | $383 | $929 |
| Operating Income | – | -$123 | -$431 | -$1,078 |
| % Margin | – | -40% | -306.7% | -384.5% |
| Other Income/Exp. Net | – | $34 | $414 | $509 |
| Pre-Tax Income | – | -$89 | -$17 | -$570 |
| Tax Expense | – | $139 | -$34 | -$199 |
| Net Income | – | -$117 | $17 | -$371 |
| % Margin | – | -38% | 12% | -132.2% |
| EPS | – | -1.17 | 0.17 | -3.73 |
| % Growth | – | -788.2% | 104.6% | – |
| EPS Diluted | – | -1.17 | 0.15 | -3.73 |
| Weighted Avg Shares Out | – | 100 | 100 | 100 |
| Weighted Avg Shares Out Dil | – | 100 | 114 | 100 |
| Supplemental Information | – | – | – | – |
| Interest Income | – | $56 | $30 | $107 |
| Interest Expense | – | $2 | $0 | $1 |
| Depreciation & Amortization | – | $61 | $84 | -$5 |
| EBITDA | – | -$27 | $21 | -$1,000 |
| % Margin | – | -8.7% | 14.8% | -356.4% |